Cell cycle of synovial fibroblasts (N/A)

The cell cycle of synovial fibroblasts refers to the regulatory process of division and replication in fibroblast-like synoviocytes (FLS), which becomes pathologically accelerated in inflammatory joint diseases such as Rheumatoid Arthritis (RA). In the RA synovium, these fibroblasts exhibit a 'tumor-like' phenotype characterized by aggressive proliferation, resistance to apoptosis, and the formation of an invasive pannus that destroys articular cartilage and bone (Bottini & Firestein, 2013, Nature Reviews Rheumatology). This hyperproliferative state is driven by the dysregulation of various cell cycle checkpoints, including the overexpression of Cyclin-dependent kinases (CDKs) and cyclins, as well as the functional loss or downregulation of tumor suppressors like p53 and p21 (Nemanich et al., 2018, Annals of the Rheumatic Diseases). While not a single molecular target itself, the 'cell cycle' represents a therapeutic axis where specific proteins like CDK4 and CDK6 are targeted to arrest the expansion of the synovial lining. Current research explores repositioning oncology-grade CDK inhibitors to reduce synovial hyperplasia and joint inflammation (Aisner & Lowder, 2003, Clinical Cancer Research). Targeting this process aims to restore synovial homeostasis and prevent the destructive invasive growth typical of chronic inflammatory arthritis.

Other names

Fibroblast-like synoviocyte (FLS) proliferationSynovial fibroblast cell cycle pathwaySynovial hyperplasiaRA-FLS proliferation

Inhibition of cyclin-dependent kinases (e.g., CDK4/6) to induce G1 cell cycle arrest or interference with pyrimidine/purine synthesis to inhibit DNA replication (e.g., via DHFR or DHODH inhibition).